HR Execs on the Move

Kymera Therapeutics

www.kymeratx.com

 
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kymeratx.com
  • 200 Arsenal Yards Boulevard Suite 230
    Watertown, MA USA 02472
  • Phone: 857.285.5300

Executives

Name Title Contact Details
Mark McClanahan
Chief Financial Officer (CFO) Profile
Eric Robertson
Sr. Director, RandD QA Profile
Karen Weisbach
Vice President People Culture Profile

Similar Companies

ClearTrial

ClearTrial, LLC is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NY CREATES

NY CREATES is a world leading R&D, innovation hub and commercialization facilitator that works with researchers in industry, academia and national labs to leverage the state of the art infrastructure in upstate New York and to partner with NY CREATES’ ...

Sirius Medicine

Sirius Medicine is a Loveland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Health Services

Meridian Health Services provides a safe, medically-supervised environment that respects your privacy and supports your physical and emotional health.

BioSig Technologies

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.